Premium
Trump's HHS eliminates x‐waiver in last days of administration
Author(s) -
Knopf Alison
Publication year - 2021
Publication title -
alcoholism and drug abuse weekly
Language(s) - English
Resource type - Journals
eISSN - 1556-7591
pISSN - 1042-1394
DOI - 10.1002/adaw.32949
Subject(s) - waiver , administration (probate law) , addiction medicine , substance abuse , medicine , mental health , medicaid , government (linguistics) , addiction , buprenorphine , opioid use disorder , harm reduction , psychiatry , health care , family medicine , political science , law , human immunodeficiency virus (hiv) , opioid , linguistics , philosophy , receptor
The federal government's Jan. 14, 5 p.m. announcement that it would remove the eight‐hour training requirement for buprenorphine prescribers in order to facilitate treatment for opioid use disorders (OUD) during the increasing overdose epidemic was met with approval by harm‐reduction advocates and the American Medical Association (AMA). However, addiction treatment advocates, including the American Society of Addiction Medicine (ASAM), which appeared to be blindsided by the announcement; H. Westley Clark, M.D., J.D., former director of the Center for Substance Abuse Treatment at the Substance Abuse and Mental Health Services Administration (SAMHSA); David A. Fiellin, M.D., director of the Program in Addiction Medicine and Professor of Medicine, Emergency Medicine and Public Health at the Yale School of Medicine; and Elinore McCance‐Katz, M.D., Ph.D., who abruptly resigned from her position as SAMHSA administrator because of her disgust at President Trump's incitement of the Jan. 6 riots on Capitol Hill (see ADAW , Jan. 18), all expressed varying degrees of reservations about the policy.